Cours Takeda Pharmaceutical Company Limited Sapporo S.E.
Actions
4502
JP3463000004
Produits pharmaceutiques
Temps Différé
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
4 300 JPY | -1,15% | -.--% | +8,18% |
CA 2024 | 4 264 Md 27,38 Md 24,38 Md | CA 2025 * | 4 252 Md 27,3 Md 24,31 Md | Capitalisation | 6 613 Md 42,47 Md 37,82 Md |
---|---|---|---|---|---|
Résultat net 2024 | 144 Md 925 M 824 M | Résultat net 2025 * | 116 Md 748 M 666 M | VE / CA 2024 | 1,54 x |
Dette nette 2024 * | 3 771 Md 24,22 Md 21,56 Md | Dette nette 2025 * | 4 224 Md 27,13 Md 24,16 Md | VE / CA 2025 * | 2,55 x |
PER 2024 |
45,4
x | PER 2025 * |
59,8
x | Employés | - |
Rendement 2024 |
4,49% | Rendement 2025 * |
4,6% | Flottant | 99,12% |
Dernier transcript sur Takeda Pharmaceutical Company Limited
1 mois | +2,63% | ||
3 mois | +4,62% | ||
6 mois | -2,27% | ||
Année en cours | +8,18% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01/04/14 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/02/22 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01/01/12 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Director/Board Member | 71 | 01/06/16 | |
Ian Clark
BRD | Director/Board Member | 62 | 01/01/19 |
Steven Gillis
BRD | Director/Board Member | 71 | 01/01/19 |
Nom | PEA | Position | Varia. 1 janv. | Notation |
---|---|---|---|---|
FCH M&G GLOBAL DIVIDEND P EUR ACC | Non | 3.76M EUR | +8,00% | |
VISIONFUND JAPAN EQUITY VAL N JPY ACC | Non | 1462.27M JPY | +15,00% | |
BNPP SUST JAPAN MLT-FAC EQ CL JPY ACC | Non | 69.59M JPY | +21,00% | |
M&G (LUX) GLB DIVIDEND A EUR ACC | Non | 119.89M EUR | +8,00% | |
CANDRIAM SST EQ JAPAN I JPY ACC | Non | 734.03M JPY | +10,00% |
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+42,69% | 750 Md | |
+34,11% | 606 Md | |
-6,87% | 356 Md | |
+18,74% | 326 Md | |
+6,76% | 286 Md | |
+18,08% | 246 Md | |
-3,44% | 213 Md | |
+11,35% | 213 Md | |
+2,64% | 167 Md |
- Bourse
- Actions
- Action 4502
- Action 4502